Its beginning to be spelled out in an extraordinary way. PYC has undergone a dramatic transformation and is in:
reach of the clinic with its first molecule
developed the capability to design RNA therapeutics
established the expertise through collaborations to go from bench to bedside re: clinical trials
connected with the strategic vision to use antisense oligonucleotides to cure rare genetic disorders
It all sounds a bit like Sarepta but with one key difference. PYC has spent the past 13 years perfecting the machinery to drive the intracellular delivery of drugs. Over the years it has toyed with many cargoes until finally it has settled upon one: neutrally charged morpholino oligonucleotides with a phoshorodiamidate backbone or linkage.
If the future of RNA therapeutics is all about solving the delivery problem, the city of Perth may have found an elegant solution.
PYC Price at posting:
6.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)